Replimune Group (NASDAQ:REPL) Shares Gap Up to $11.03

Replimune Group, Inc. (NASDAQ:REPL) shares gapped up prior to trading on Wednesday . The stock had previously closed at $11.03, but opened at $11.27. Replimune Group shares last traded at $11.43, with a volume of 15,854 shares changing hands.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on REPL. HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research note on Monday. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Wedbush restated an “outperform” rating and set a $16.00 price target on shares of Replimune Group in a research report on Thursday, June 6th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and a consensus price target of $16.20.

Replimune Group Price Performance

The stock’s 50-day moving average price is $10.19 and its 200 day moving average price is $8.38. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $701.97 million, a price-to-earnings ratio of -3.40 and a beta of 1.22.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Equities research analysts expect that Replimune Group, Inc. will post -3.08 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.60% of the company’s stock.

Institutional Trading of Replimune Group

Hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new position in Replimune Group in the first quarter valued at approximately $927,000. BNP Paribas Financial Markets lifted its stake in shares of Replimune Group by 517.9% in the 4th quarter. BNP Paribas Financial Markets now owns 196,251 shares of the company’s stock valued at $1,654,000 after purchasing an additional 164,490 shares during the last quarter. Clearbridge Investments LLC purchased a new position in shares of Replimune Group during the 4th quarter worth $2,282,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Replimune Group during the 1st quarter worth about $1,088,000. Finally, Rafferty Asset Management LLC increased its position in shares of Replimune Group by 148.1% during the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after purchasing an additional 276,596 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.